Lung Cancer Patients to Access Erlotinib-Gefitinib as First-Line Treatment
Bangkok: Starting December 1, lung cancer patients are now able to use “Erlotinib-Gefitinib” as their first-line treatment. This development is aimed at controlling the disease for nine months to one year, particularly in cases involving mutations that accelerate cancer growth. According to Thai News Agency, Ms. Ayrin Phanrit, Deputy Government Spokesperson, announced that the Comptroller General’s Department has revised its